Modality
Radioligand
MOA
CDK2i
Target
TROP-2
Pathway
Incretin
Crohn'sAS
Development Pipeline
Preclinical
~Dec 2016
→ ~Mar 2018
Phase 1
~Jun 2018
→ ~Sep 2019
Phase 2
~Dec 2019
→ ~Mar 2021
Phase 3
Jun 2021
→ Apr 2027
Phase 3Current
NCT06705741
2,137 pts·Crohn's
2022-09→2025-11·Recruiting
NCT08829104
1,912 pts·Crohn's
2021-06→2027-04·Active
NCT04082724
2,436 pts·AS
2021-06→2025-01·Completed
6,485 total pts2 indications
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (3)
2025-01-091.2y agoPh3 Readout· AS
2025-11-194mo agoPh3 Readout· Crohn's
2027-04-201.1y awayPh3 Readout· Crohn's
Trial Timeline
Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2
P3
Active
P3
Complet…
P3
Recruit…
Catalysts
Ph3 Readout
2025-01-09 · 1.2y ago
AS
Ph3 Readout
2025-11-19 · 4mo ago
Crohn's
Ph3 Readout
2027-04-20 · 1.1y away
Crohn's
RecruitingActiveCompleted|StartCompletionToday
Trials (3)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06705741 | Phase 3 | Crohn's | Recruiting | 2137 | PFS |
| NCT08829104 | Phase 3 | Crohn's | Active | 1912 | Safety |
| NCT04082724 | Phase 3 | AS | Completed | 2436 | LiverFat |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-3703 | Pfizer | Phase 1/2 | CDK2 | |
| Tirafotisoran | Roche | Phase 2 | CD38 | |
| NVS-4076 | Novartis | Preclinical | TROP-2 | |
| NVS-8902 | Novartis | Preclinical | TROP-2 | |
| ABB-3951 | AbbVie | Phase 2/3 | TNFα | |
| AZN-6870 | AstraZeneca | Phase 2/3 | EGFR | |
| Zanumavacamten | GSK | Phase 2/3 | TROP-2 | |
| Tirasotorasib | Takeda | NDA/BLA | IL-17A | |
| Mavuglumide | Bayer | Approved | GLP-1R | |
| DSN-3066 | Daiichi Sankyo | Phase 3 | IL-13 |